Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) research hub
7 indexed studies · 4 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
This trial looks at a targeted radioactive medicine called Radium-223 for people with advanced prostate cancer that has spread to the bones. Doctors want to see if patients can comfortably complete at least five doses of this injection alongside their standard care to help control the disease.
Spain - recruitingPHASE3
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
This study is for men with prostate cancer that has spread and is still responding to hormone treatment, after recent docetaxel or Lu-PSMA therapy. It tests a new drug called saruparib combined with standard hormone treatment, to see if it works better than standard treatment alone.
United States · Austria · Brazil - recruitingTherapeutic confirmatory (Phase III)
(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).
This study looks at a new drug, darolutamide, for men with prostate cancer that has spread and still responds to hormone therapy. It compares darolutamide plus standard hormone therapy to a dummy pill plus standard hormone therapy, to see if darolutamide helps patients live longer without their cancer getting worse.
Spain · Latvia · Lithuania - active not recruitingPHASE3
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
This study compares two ways of giving a prostate cancer drug, Docetaxel, along with standard treatments Darolutamide and ADT. It aims to find out which schedule causes fewer serious side effects in men with advanced prostate cancer.
Austria · Germany - recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
This study is gathering information on men with prostate cancer that has come back or spread. It looks at how their condition progresses and how treatments work in real life. It aims to help us understand the best ways to manage different stages of prostate cancer.
Germany - recruitingPHASE1, PHASE2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This study looks at new combinations of medicines for men with prostate cancer that has spread. It checks if combining a new drug, tulmimetostat, with existing treatments like darolutamide or abiraterone is safe and works well. The goal is to find better ways to treat this type of cancer.
United States · Australia · Brazil - active not recruiting
Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients
This study looks at how a medicine called apalutamide works for men with prostate cancer that has spread. It checks if the medicine helps, how it affects daily life, and gathers real-world information beyond strict trials.
United Kingdom